Catherine M. Szyman - 17 May 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Critical Care
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
17 May 2021
Net transactions value
-$830,288
Form type
4
Filing time
19 May 2021, 16:31:15 UTC
Previous filing
12 May 2021
Next filing
24 May 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +15,225 +53% $0.000000 43,709 17 May 2021 Direct F1
transaction EW Common Stock Tax liability $154,728 -1,729 -4% $89.49 41,980 17 May 2021 Direct
transaction EW Common Stock Tax liability $675,560 -7,549 -18% $89.49 34,431 17 May 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -15,225 -100% $0.000000* 0 17 May 2021 Common Stock 15,225 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.